Pyridine based dual binding site aromatase (CYP19A1) inhibitors-Reference-Cited by-同舟云学术

Pyridine based dual binding site aromatase (CYP19A1) inhibitors

Published:2023 Issue:2 Volume:14 Page:356-366
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Eissa Ahmed G.¹,Powell Lauren E.²,Gee Julia¹,Foster Paul A.²³,Simons Claire¹^ORCID

Affiliation:

1. School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3NB UK

2. Institute of Metabolism & Systems Research (IMSR), University of Birmingham, Birmingham B15 2TT, UK

3. Centre for Endocrinology, Diabetes, and Metabolism, Birmingham Health Partners, Birmingham, B15 2TT, UK

Abstract

4th generation pyridine based dual site aromatase (CYP19A1) inhibitors were synthesised and evaluated for CYP19A1 inhibitory activity, cytotoxicity and CYP selectivity. Computational studies provided insight into the potential binding mode.

Funder

European Regional Development Fund

Ministry of Higher Education, Egypt

Zagazig University

Cardiff University

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MD/D2MD00352J

Reference21 articles.

1. Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure–Function Perspective

2. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists

3. Acquired resistance to aromatase inhibitors: where we stand!

4. 1-[(Benzofuran-2-yl)phenylmethyl]-triazoles and -tetrazoles - potent competitive inhibitors of aromatase

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs;Molecules;2024-01-10